We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold on to Varian (VAR) Stock for Now
Read MoreHide Full Article
Varian Medical Systems, Inc. is likely to gain from strong fourth-quarter fiscal 2019 results and a slew of positive developments. However, the company has been experiencing weakness in its Proton Therapy revenues.
In a year’s time, shares of Varian have rallied 12.1% compared with the industry’s 11% rise. Meanwhile, the S&P 500 Index has risen 17.9%.
With a market capitalization of $11.98 billion, Varian is the world’s leading provider of radiotherapy, radiosurgery, proton therapy and brachytherapy for treating cancer and other medical conditions. The company’s earnings are anticipated to grow 8% over the next five years. For the trailing four quarters, the company has a positive earnings surprise of 1.6%, on average.
Let’s take a closer look at the factors that substantiate Varian’s Zacks Rank #3 (Hold).
Factors to Boost Varian
In the recently-reported fourth quarter, Varian posted earnings per share (EPS) of $1.21, in line with the Zacks Consensus Estimate. Adjusted EPS rose 4.3% year over year.
The company reported revenues of $878.9 million, which surpassed the consensus mark of $853.3 million. On a year-over-year basis, revenues rose 9.6% and 12% at constant currency (cc).
Notably, Oncology revenues increased 8.5% year over year and 11% at cc, driven by an expansion of the company’s net installed base. Gross orders grew 7% from the year-ago quarter to $1.1 billion.
Apart from this, Varian has seen a slew of developments of late.
For instance, South Florida Proton Therapy Institute, an International facility has treated its first patient utilizing the Varian ProBeam Compact single-room proton therapy system. Notably, Varian’s proton therapy is one of the most advanced radiation treatments available.
Earlier this month, management at Varian announced that the company has been selected as the vendor of choice by the Michigan Oncology Quality Consortium to support its efforts to develop patient-centered quality measures for cancer care.
Last month, Australia's Icon Group made a purchase order to improve the quality of cancer care treatment across its international network. The order includes a significant suite of Varian’s cancer treatment hardware and software, including a purchase of Ethos therapy, an adaptive intelligence solution.
In the fiscal fourth quarter, Varian’s Proton Therapy revenues contracted 8.9%. Additionally, APAC orders declined 9% year over year owing to softness in Japan.
That’s not all. Varian faces stiff competition from large electronic companies such as Siemens and Philips as well as smaller and more specialized radiation therapy equipment manufacturers like Elekta, Accuray, Philips, Medtronic (MDT - Free Report) and Stryker (SYK - Free Report) .
Which Way Are Estimates Headed?
For fiscal 2020, the Zacks Consensus Estimate for revenues is pegged at $3.57 billion, indicating an improvement of 10.5% from the year-ago reported figure. For adjusted earnings, the same stands at $5.39 per share, suggesting growth of 16.4% from the year-ago reported figure.
Conmed has a long-term earnings growth rate of 17%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
Image: Bigstock
Here's Why You Should Hold on to Varian (VAR) Stock for Now
Varian Medical Systems, Inc. is likely to gain from strong fourth-quarter fiscal 2019 results and a slew of positive developments. However, the company has been experiencing weakness in its Proton Therapy revenues.
In a year’s time, shares of Varian have rallied 12.1% compared with the industry’s 11% rise. Meanwhile, the S&P 500 Index has risen 17.9%.
With a market capitalization of $11.98 billion, Varian is the world’s leading provider of radiotherapy, radiosurgery, proton therapy and brachytherapy for treating cancer and other medical conditions. The company’s earnings are anticipated to grow 8% over the next five years. For the trailing four quarters, the company has a positive earnings surprise of 1.6%, on average.
Let’s take a closer look at the factors that substantiate Varian’s Zacks Rank #3 (Hold).
Factors to Boost Varian
In the recently-reported fourth quarter, Varian posted earnings per share (EPS) of $1.21, in line with the Zacks Consensus Estimate. Adjusted EPS rose 4.3% year over year.
The company reported revenues of $878.9 million, which surpassed the consensus mark of $853.3 million. On a year-over-year basis, revenues rose 9.6% and 12% at constant currency (cc).
Notably, Oncology revenues increased 8.5% year over year and 11% at cc, driven by an expansion of the company’s net installed base. Gross orders grew 7% from the year-ago quarter to $1.1 billion.
Apart from this, Varian has seen a slew of developments of late.
For instance, South Florida Proton Therapy Institute, an International facility has treated its first patient utilizing the Varian ProBeam Compact single-room proton therapy system. Notably, Varian’s proton therapy is one of the most advanced radiation treatments available.
Earlier this month, management at Varian announced that the company has been selected as the vendor of choice by the Michigan Oncology Quality Consortium to support its efforts to develop patient-centered quality measures for cancer care.
Last month, Australia's Icon Group made a purchase order to improve the quality of cancer care treatment across its international network. The order includes a significant suite of Varian’s cancer treatment hardware and software, including a purchase of Ethos therapy, an adaptive intelligence solution.
Varian Medical Systems, Inc. Price and Consensus
Varian Medical Systems, Inc. price-consensus-chart | Varian Medical Systems, Inc. Quote
What’s Deterring the Stock?
In the fiscal fourth quarter, Varian’s Proton Therapy revenues contracted 8.9%. Additionally, APAC orders declined 9% year over year owing to softness in Japan.
That’s not all. Varian faces stiff competition from large electronic companies such as Siemens and Philips as well as smaller and more specialized radiation therapy equipment manufacturers like Elekta, Accuray, Philips, Medtronic (MDT - Free Report) and Stryker (SYK - Free Report) .
Which Way Are Estimates Headed?
For fiscal 2020, the Zacks Consensus Estimate for revenues is pegged at $3.57 billion, indicating an improvement of 10.5% from the year-ago reported figure. For adjusted earnings, the same stands at $5.39 per share, suggesting growth of 16.4% from the year-ago reported figure.
A Stock to Consider
A better-ranked stock in the broader medical sector is Conmed Corporation (CNMD - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Conmed has a long-term earnings growth rate of 17%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
See their latest picks free >>